Targeted RNA Sequencing of VZV-Infected Brain Vascular Adventitial Fibroblasts Indicates That Amyloid May Be Involved in VZV Vasculopathy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 7, 2021
- Accepted in final form September 9, 2021
- First Published November 10, 2021.
Author Disclosures
- Andrew N. Bubak, PhD (andrew.bubak{at}cuanschutz.edu),
- Christina N. Como, BA (christina.como{at}cuanschutz.edu),
- James E. Hassell Jr, PhD (james.hasselljr{at}cuanschutz.edu),
- Teresa Mescher, MPH (teresa.mescher{at}cuanschutz.edu),
- Seth E. Frietze, PhD (seth.frietze{at}med.uvm.edu),
- Christy S. Niemeyer, PhD (christy.niemeyer{at}cuanschutz.edu),
- Randall J. Cohrs, PhD (randall.cohrs{at}cuanschutz.edu) and
- Maria A. Nagel, MD (maria.nagel{at}ucdenver.edu)
- Andrew N. Bubak, PhD (andrew.bubak{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
ÂNeurokinin-1 receptor antagonists for the treatment of alphaherpesvirusesÂ, United States Patent, 2848-295-PROV.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christina N. Como, BA (christina.como{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- James E. Hassell Jr, PhD (james.hasselljr{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Teresa Mescher, MPH (teresa.mescher{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Seth E. Frietze, PhD (seth.frietze{at}med.uvm.edu),
NONE
NONE
NONE
(1) International Journal of Molecular Sciences, editorial advisory board member, 2 years (2) Life, editorial advisory board member, <1 year (3) BioMedInformatics, editorial advisory board member, <1 year
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)NIH, P01CA240685, PI, 2021-2025 (2)NSF, OIA-1736097, co-PI, 2017-2022 (3)NIH, R01CA230618, PI, 2017-2022 (4)NIH, R01AI127709, PI, 2017-2022 (5)NIH, R01GM129338-01, PI, 2018-2023 (6)NIH, P01AG0325958-11, subaward, 2019-2024
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christy S. Niemeyer, PhD (christy.niemeyer{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Randall J. Cohrs, PhD (randall.cohrs{at}cuanschutz.edu) and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria A. Nagel, MD (maria.nagel{at}ucdenver.edu)
(1) Zoster Eye Disease Study (ZEDS), National Eye Institute, National Institutes of Health, Member, Data Safety Monitoring Committee
NONE
(1) GlaxoSmithKline (GSK), travel and hotel expenses paid, Member, VZV Vasculopathy Advisory Board (2019 meeting)
(1) Journal of Neurovirology, Editorial Board (Associate Editor), 2015-present
(1) Neurokinin-1 receptor antagonists for the treatment of alphaherpesviruses, United State Patent 2848-295-PROV.
(1) Stroke caused by varicella zoster virus; UpToDate, Wolters Kluwer Health, first published 2018 and with udates; royalties paid yearly
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH/NIA P01 AG032958, Co-Project Leader, Project 1, 03/01/2009-12/31/2023; (2) NIH/NINDS R01 NS093716, Co-investigator, 07/01/2015- 06/30/2021; (3) NIH/NIDCD R01 DC00566, Co-investigator, 05/01/2020- 04/30/2021 (4) NIH/NIDCD R01 DC014253, Co-investigator, 08/01/2019- 07/30/21 (5) NIH R01 NS094758, Principal Investigator, 09/01/15- 08/31/20
(1) SPARK/REACH Program, University of Colorado Anschutz Medical Campus, Principal Investigator, 09/01/2020-08/31/2022
NONE
NONE
NONE
NONE
NONE
NONE
(1) Merck (Venable LLP), written report, expert witness
- From the Department of Neurology (A.N.B., C.N.C., J.E.H., T.M., C.S.N., R.J.C., M.A.N.), University of Colorado; Department of Medical Laboratory Sciences (S.E.F.), University of Vermont, Burlington, VT; Department of Immununology & Microbiology (R.J.C.), University of Colorado; and Department of Ophthalmology (M.A.N.), University of Colorado, Aurora, CO.
- Correspondence
Dr. Nagel maria.nagel{at}ucdenver.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.